Skip to content

Tracking Outcomes in Psychosis

Tracking Outcomes in Psychosis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02882204
Acronym
TOPSY
Enrollment
168
Registered
2016-08-29
Start date
2016-03-01
Completion date
2023-12-01
Last updated
2020-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

The investigators propose to study the brain processes that result in thought and language disorder and influence outcomes seen in patients with schizophrenia using a combination of brain scans and clinical assessments. The project will assess patients at various stages of psychosis (Clinical high risk, first episode and chronic stage \>3 years of illness) referred to the Prevention and Early Intervention in Psychosis Programme using Magnetic Resonance Imaging (MRI scans). To track the outcome of this illness, investigators will follow-up patients over 3 years and collect MRI scans over four sessions for each first episode patient, and two sessions for clinical high risk patients, chronic patients, and healthy controls. Participants will also complete a clinical assessment examining symptoms and functioning as per the current clinical practice within the PEPP program at each scanning session.

Detailed description

OBJECTIVES: The objective of this study is to investigate the pathophysiology of Formal Thought Disorder and variable outcomes in the early stages of schizophrenia. In particular, investigators aim to test the hypothesis that 1. Anatomical abnormalities involving the grey matter of the Anterior Insula and Medial Prefrontal Cortex in first episode schizophrenia predicts FTD that persists by 6 months of illness 2. An excess of glutamine/glutamate, or reduction in glutathione, in Medial Prefrontal Cortex at index episode will be associated with persistent FTD 3.Aberrant connectivity between Anterior Insula and Medial Prefrontal Cortex will specifically predict the severity of persistent FTD irrespective of the stage of illness; the change in this connectivity will track the variable 3-year outcome among patients with first episode of psychosis. METHODS: This study will employ a cross-sectional design recruiting n=126 participants from the Prevention & Early Intervention Program for Psychoses (PEPP). Four groups of participants will be assessed: patients at a later stage of schizophrenia (chronic illness group) (n=42), newly referred first episode group of PEPP patients (n=84), Clinical High Risk patients (n=60) and healthy Controls (n=45). Measurements: Patients will be diagnosed using the criteria for schizophrenia according to DSM-V(34). Demographic variables such as age, gender and parental socioeconomic status will be recorded to adjust for potential confounding effects. Patients will undergo baseline assessments to assess seven features of FTD (poverty of speech, weakening of goal, perseveration, looseness, peculiar word usage, peculiar sentence usage and peculiar logic) in line with the validated procedure for administering Thought Language Index \[TLI\](17). First episode patients will undergo four 7T MRI scanning sessions over the course of 2.5 years (baseline, 6 months, 18 months, 30 months)lasting for 60 minutes each, as described in our previous work (15). During this time, researchers will perform MR spectroscopy (MPFC voxel (31)), T1 weighted structural scan and eyes-closed, task-free, 6 minutes resting-state functional MRI. 6 months after the onset of first episode, the clinical assessment will be repeated using TLI. Patients with persistent FTD will be identified (from previous studies, 40% of patients are expected to have persistent FTD (9)) and separated from patients who have no FTD at 6-months time point. Patients with established illness will undergo only 2 scans: baseline and 1 year later.

Interventions

None listed

Sponsors

University of Western Ontario, Canada
CollaboratorOTHER
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* 16-45 years old * Outpatient of the Prevention and Early Intervention Program for Psychosis

Exclusion criteria

* Drug or alcohol dependence in past year * History of head injury (with associated unconsciousness for any period) * Mental retardation or suffering from medical conditions such as untreated hypertension, diabetes, hepatic/renal insufficiency, neurological illnesses * Otherwise unable to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Change in Thought Language Index Score between baseline and 6 months6 MonthsPredicting the change in TLI score based on baseline anatomical abnormalities identified through MRI
Time to remission of positive symptoms of psychosis30 monthsThe time between baseline and remission of positive symptoms based on PANSS-8
Time to remission of negative symptoms of psychosis30 monthsThe amount of time between baseline and remission of negative symptoms based on PANSS-8
Emergence of treatment resistance using operational criteria30 months

Secondary

MeasureTime frameDescription
Change in overall symptoms over time30 monthsTracking changes in scores on the PANSS-8 over the 30 months of follow up for first episode patients
Changes in myelin content30 months (follow up period for first episode patients)Longitudinal changes in myelin content as measured using quantitative t1 images
Change in Thought Language Index score between baseline and longitudinal follow up-dates (12 months, 18 months, 24 months and 30 months)1-2.5 yearsNet change in TLI score as predicted by anatomical abnormalities associated with imaging at various imaging time points.

Countries

Canada

Contacts

Primary ContactLena Palaniyappan, MD, PhD
lena.palaniyappan.@lhsc.on.ca519.685.8054

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026